Symbol | Exchange | Currency |
|---|
Investing.com – U.S. equities were higher at the close on Friday, as gains in the Oil & Gas, Basic Materials and Financials sectors propelled shares higher. At the close in NYSE,...
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Oil & Gas, Financials and Industrials sectors propelled shares higher. At the close in NYSE,...
By Dhirendra TripathiInvesting.com – Cassava Sciences (NASDAQ:SAVA) stock plummeted 20% Wednesday even as the company defended itself against allegations questioning its...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 109.40 | 109.98 | 108.98 | -0.04 | -0.04% | 5.47M | London | |||
| 101.90 | 102.55 | 101.00 | +1.65 | +1.65% | 2.89M | London | |||
| 432.15 | 432.60 | 430.00 | -0.65 | -0.15% | 2.50M | London | |||
| 23.30 | 23.30 | 23.30 | -0.50 | -2.13% | 1.44M | London | |||
| 423.70 | 424.20 | 420.60 | +2.00 | +0.47% | 584.16K | London | |||
| 3,400.00 | 3,503.00 | 3,400.00 | +48.0 | +1.43% | 12.29K | London | |||
| 1,260.00 | 1,265.50 | 1,258.00 | -1.00 | -0.08% | 126.90K | London | |||
| 395.95 | 397.80 | 394.20 | +3.50 | +0.89% | 8.54M | London | |||
| 311.60 | 311.60 | 307.00 | -1.00 | -0.32% | 53.01K | London | |||
| 1,796.50 | 1,829.00 | 1,794.50 | -17.0 | -0.94% | 85.59K | London | |||
| 49.44 | 49.51 | 49.01 | +0.16 | +0.33% | 10.04M | London | |||
| 4.87 | 4.90 | 4.85 | +0.02 | +0.43% | 7.03M | London | |||
| 954.60 | 972.50 | 953.00 | +7.50 | +0.79% | 41.65K | London | |||
| 141.36 | 142.98 | 140.80 | -1.40 | -0.98% | 5.33M | London | |||
| 171.22 | 173.94 | 169.54 | -4.50 | -2.56% | 8.91M | London |
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimers disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimers brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimers disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimers disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.